- Home
- SKYE vs EXFY Comparison
SKYE vs EXFY Comparison
Compare SKYE & EXFY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SKYE
- EXFY
- Stock Information
- Founded
- SKYE 2012
- EXFY 2008
- Country
- SKYE United States
- EXFY United States
- Employees
- SKYE N/A
- EXFY N/A
- Industry
- SKYE Biotechnology: Pharmaceutical Preparations
- EXFY Computer Software: Prepackaged Software
- Sector
- SKYE Health Care
- EXFY Technology
- Exchange
- SKYE Nasdaq
- EXFY Nasdaq
- Market Cap
- SKYE 172.9M
- EXFY 162.6M
- IPO Year
- SKYE N/A
- EXFY 2021
- Fundamental
- Price
- SKYE $5.31
- EXFY $2.27
- Analyst Decision
- SKYE Strong Buy
- EXFY Hold
- Analyst Count
- SKYE 5
- EXFY 6
- Target Price
- SKYE $18.40
- EXFY $2.63
- AVG Volume (30 Days)
- SKYE 146.6K
- EXFY 477.7K
- Earning Date
- SKYE 11-09-2024
- EXFY 11-05-2024
- Dividend Yield
- SKYE N/A
- EXFY N/A
- EPS Growth
- SKYE N/A
- EXFY N/A
- EPS
- SKYE N/A
- EXFY N/A
- Revenue
- SKYE N/A
- EXFY $138,525,000.00
- Revenue This Year
- SKYE N/A
- EXFY N/A
- Revenue Next Year
- SKYE N/A
- EXFY $6.84
- P/E Ratio
- SKYE N/A
- EXFY N/A
- Revenue Growth
- SKYE N/A
- EXFY N/A
- 52 Week Low
- SKYE $1.44
- EXFY $1.24
- 52 Week High
- SKYE $19.41
- EXFY $3.47
- Technical
- Relative Strength Index (RSI)
- SKYE 42.98
- EXFY 50.01
- Support Level
- SKYE $5.71
- EXFY $2.21
- Resistance Level
- SKYE $7.11
- EXFY $2.52
- Average True Range (ATR)
- SKYE 0.58
- EXFY 0.20
- MACD
- SKYE -0.05
- EXFY -0.03
- Stochastic Oscillator
- SKYE 0.55
- EXFY 26.37
About SKYE Skye Bioscience Inc. Common Stock
Skye Bioscience Inc is a pre-clinical pharmaceutical company located in San Diego, California. The company's clinical assets focus on the modulation of cannabinoid receptor 1 ("CB1") to provide novel treatments and alternatives for diseases caused by metabolic disorders, inflammation, fibrosis and neurodegeneration, such as obesity and glaucoma. The company's Phase 2 clinical candidates include nimacimab, a negative allosteric modulating antibody that inhibits peripheral CB1 receptors, currently being developed for the treatment of obesity and SBI-100 Ophthalmic Emulsion ("SBI-100 OE"), a CB1 agonist (activator), currently being developed for the treatment of glaucoma and ocular hypertension.
About EXFY Expensify Inc.
Expensify Inc is a cloud-based expense management software platform that helps various businesses simplify the way to manage money. It is used to scan and reimburse receipts from flights, hotels, coffee shops, office supplies and ride shares. People use Expensify's free features, which include corporate cards, expense tracking, next-day reimbursement, invoicing, bill pay, and travel booking in one app.